The aim of the study was to estimate the influence of interactions between peroxisome proliferator-activated receptor γ (PPARγ) and target genes lipoprotein lipase (LPL), interleukin 6 (IL6), angiotensin converting enzyme (ACE), and angiotensin II type 1 receptor (AT1R) on metabolic syndrome (MetSy) and its traits.
Methods:
The study included 527 participants (263 with MetSy and 264 controls). Genotyping of PPARγ Pro12Ala, LPL PvuII (−/+), IL6 -174G>C, ACE I/D and AT1R 1166A>C was performed using polymerase chain reaction-restriction fragment length polymorphism-based methods. Results: Interaction between PPARγ Pro12Ala and LPL Pvu(−/+) improved prediction of MetSy over and above prediction based on a model containing no interactions (χ2=7.22; df=1; p=0.007). In the group of participants with PPARγ Pro12Ala or Ala12Ala genotypes, those with the LPL Pvu (−/+) or (+/+) genotype had greater odds for MetSy (odds ratio OR=5.98; 95% confidence interval CI: 1.46-24.47, p=0.013). Interaction between PPARγ Pro12Ala and IL6 -174G>C improved prediction of high fasting blood glucose (χ2=13.99; df=1; p<0.001). PPARγ Ala12 variant was found protective in patients with IL6 -174GG genotype (OR=0.10; 95% CI: 0.02-0.57, p=0.01), while in the case of IL6 -174C allele carriers, for PPARγ Ala12 carriers, larger odds for high glucose levels compared with Pro12 variant were observed (OR=2.39; 95% CI: 1.11-5.17, p=0.026). Interactions of PPARγ and ACE were significant for BMI. In the group with ACE DD genotype, those with PPARγ Pro12Ala or Ala12Ala genotype have greater odds for obesity (OR=9.98; 95% CI: 1.18-84.14, p=0.034). Conclusions:PPARγ gene variants can, in interaction with some of its target genes, modulate physiological processes leading to the development of MetSy.
Get full access to this article
View all access options for this article.
References
1.
AngelakopoulouA, ShahT, SofatR, et al. (2012) Comparative analysis of genome-wide association studies signals for lipids, diabetes, and coronary heart disease: cardiovascular biomarker genetics collaboration. Eur Heart J, 33:393-407.
Bell-ParikhLC, IdeT, LawsonJA, et al. (2003) Biosynthesis of 15-deoxydelta12,14-PGJ2 and the ligation of PPARgamma. J Clin Invest, 112:945-955.
4.
BerthierMT, ParadisAM, TchernofA, et al. (2003) The interleukin 6-174G/C polymorphism is associated with indices of obesity in men. J Hum Genet, 48:14-19.
5.
BhattSP, MisraA, SharmaM, et al. (2012) Ala/Ala genotype of Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-γ2 gene is associated with obesity and insulin resistance in Asian Indians. Diabetes Technol Ther, 14:828-834.
6.
BonnardeauxA, DaviesE, JeunemaitreX, et al. (1994) Angiotensin II type 1 receptor gene polymorphisms in human essential hypertension. Hypertension, 24:63-69.
7.
CurtiML, JacobP, BorgesMC, et al. (2011) Studies of gene variants related to inflammation, oxidative stress, dyslipidemia, and obesity: implications for a nutrigenetic approach. J Obes, 2011:497401
8.
DamcottCM, MoffettSP, FeingoldE, et al. (2004) Genetic variation in fatty acid-binding protein-4 and peroxisome proliferator-activated receptor gamma interactively influence insulin sensitivity and body composition in males. Metabolism, 53:303-309.
9.
de RooijSR, PainterRC, PhillipsDI, et al. (2006) The effects of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma2 gene on glucose/insulin metabolism interact with prenatal exposure to famine. Diabetes Care, 29:1052-1057.
10.
DeebSS, FajasL, NemotoM, et al. (1998) A Pro12Ala substitution in PPARγ2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet, 20:284-287.
11.
EngeliS, NegrelR, SharmaAM (2000) Physiology and pathophysiology of the adipose tissue renin angiotensin system. Hypertension, 35:1270-1277.
12.
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. (2001) Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA, 285:2486-2497.
13.
Fernandez-RealJM, BrochM, VendrellJ, et al. (2000) Interleukin-6 gene polymorphism and lipid abnormalities in healthy subjects. J Clin Endocrinol Metab, 85:1334-1339.
14.
Fernandez-RealJM, VayredaM, RichartC, et al. (2001) Circulating interleukin 6 levels, blood pressure, and insulin sensitivity in apparently healthy men and women. J Clin Endocrinol Metab, 86:1154-1159.
15.
GoudaHN, SagooGS, HardingAH, et al. (2010) The association between the peroxisome proliferator-activated receptor-gamma2 (PPARG2) Pro12Ala gene variant and type 2 diabetes mellitus: a HuGE review and meta-analysis. Am J Epidemiol, 171:645-655.
16.
GroopL (2000) Genetics of the metabolic syndrome. Br J Nutr, 83(Suppl 1):S39-S48.
17.
HeW (2009) PPARgamma2 Polymorphism and Human Health. PPAR Res, 2009:849538.
18.
HilgersKF, LangenfeldMRW, SchlaichM, et al. (1999) 1166 A/C polymorphism of the angiotensin II type 1 receptor gene and the response to short-term infusion of angiotensin II. Circulation, 100:1394-1399.
19.
HuangHY, ThuitaL, StricklandP, et al. (2007) Frequencies of single nucleotide polymorphisms in genes regulating inflammatory responses in a community-based population. BMC Genet, 8:7.
20.
HuangX, ZhaoJ, ZhaoT (2011) Effects of peroxisome proliferator activated receptor-gamma 2 gene Pro12Ala polymorphism on fasting blood lipids: a meta-analysis. Atherosclerosis, 215:136-144.
21.
HutchC, IlligT, HerderC, et al. (2009) Joint analysis of individual participants' data from17 studies on the association of the IL-6 variant −174G>C with circulating glucose levels, interleukin-6 levels, and boy mass index. Ann Med, 41:128-138.
22.
IdeT, EganK, Bell-ParikhLC, et al. (2003) Activation of nuclear receptors by prostaglandins. Thromb Res, 110:311-315.
23.
JaccardJ (2001) Interaction Effects in Logistic Regression. Sage University Papers Series on Quantitative Applications in the Social Sciences. SAGE, Thousand Oaks, CA, pp 07-135.
24.
JamieWE, EdwardsRK, FergusonRJ, et al. (2005) The interleukin-6—174 single nucleotide polymorphism: cervical protein production and the risk of preterm delivery. Am J Obstet Gynecol, 192:1023-1027.
25.
KleinbaumDG and KleinM (2002) Logistic regression: A self learning text (2nd ed.). Springer, New York.
26.
KrajaAT, BoreckiIB, NorthK, et al. (2006) Longitudinal and age trends of metabolic syndrome and its risk factors: the Family Heart Study. Nutr Metab (Lond), 3:41.
27.
KubaszekA, PihlajamakiJ, PunnonenK, et al. (2003) The C-174G promoter polymorphism of the IL-6 gene affects energy expenditure and insulin sensitivity. Diabetes, 52:558-561.
28.
LinHF, Boden-AlbalaB, JuoSH, et al. (2005) Heritabilities of the metabolic syndrome and its components in the Northern Manhattan Family Study. Diabetologia, 48:2006-2012.
29.
LusisAJ, AttieAD, ReueK (2008) Metabolic syndrome: from epidemiology to systems biology. Nat Rev Genet, 9:819-830.
30.
MasudS, YeS; SAS Group (2003) Effect of the peroxisome proliferator activated receptor-gamma gene Pro12Ala variant on body mass index: a meta-analysis. J Med Genet, 40:773-780.
31.
MillerSA, DykesDD, PoleskyHF (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res, 16:1215.
32.
MöllstenA, StegmayrB, WiklundPG (2008) Genetic polymorphisms in the renin-angiotensin system confer increased risk of stroke independently of blood pressure: a nested case-control study. J Hypertens, 26:1367-1372.
33.
MondaKL, NorthKE, HuntSC, et al. (2010) The genetics of obesity and the metabolic syndrome. Endocr Metab Immune Disord Drug Targets, 10:86-108.
34.
OchoaMC, MartiA, AzconaC, et al. (2004) Gene-gene interaction between PPAR gamma 2 and ADR beta 3 increases obesity risk in children and adolescents. Int J Obes Relat Metab Disord, 28(Suppl 3):S37-S41.
35.
OhEY, MinKM, ChungJH, et al. (2000) Significance of Pro12Ala mutation in peroxisome proliferator-activated receptor-gamma2 in Korean diabetic and obese subjects. J Clin Endocrinol Metab, 85:1801-1804.
36.
OlefskyJM (2000) Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists. J Clin Invest, 106:467-472.
37.
PalatiniP, CeolottoG, DorigattiF, et al. (2009) Angiotensin II type 1 receptor gene polymorphism predicts development of hypertension and metabolic syndrome. Am J Hypertens, 22:208-214.
38.
ParacchiniV, PedottiP, TaioliE (2005) Genetics of leptin and obesity: a HuGE review. Am J Epidemiol, 162:101-114.
39.
ParkYM, ProvinceMA, GaoX, et al. (2009) Longitudinal trends in the association of metabolic syndrome with 550 k single-nucleotide polymorphisms in the Framingham Heart Study. BMC Proc, 3(Suppl 7):S116.
40.
PassaroA, Dalla NoraE, MarcelloC, et al. (2011) PPARγ Pro12Ala and ACE ID polymorphisms are associated with BMI and fat distribution, but not metabolic syndrome. Cardiovasc Diabetol, 10:112
41.
PujiaA, GnassoA, IraceC, et al. (1994) Association between ACE-D/D polymorphism and hypertension in type II diabetic subjects. J Hum Hypertens, 8:687-691.
42.
QiL, ZhangC, van DamRM, et al. (2007) Interleukin-6 genetic variability and adiposity: associations in two prospective cohorts and systematic review in 26,944 individuals. J Clin Endocrinol Metab, 92:3618-3625.
43.
RangwalaSM, LazarMA (2000) Transcriptional control of adipogenesis. Annu Rev Nutr, 20:535-559.
44.
RigatB, HubertC, Alhenc-GelasF, et al. (1990) An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest, 86:1343-1346.
45.
RigatB, HubertC, CorvolP, et al. (1992) PCR detection of the insertion/deletion polymorphism of the human angiotensin converting enzyme gene (DCP1) (dipeptidyl carboxypeptidase 1). Nucleic Acids Res, 20:1433
46.
RoszerT, RicoteM (2010) PPARs in the renal regulation of systemic blood pressure. PPAR Res, 2010:698730.
47.
Saint-MarcP, KozakLP, AilhaudG, et al. (2001) Angiotensin II as a trophic factor of white adipose tissue: stimulation of adipose cell formation. Endocrinology, 142:487-492.
48.
SattarN, PerryCG, PetrieJR (2003) Type 2 diabetes as an inflammatory disorder. Br J Diabetes Vasc Dis, 3:36-41.
49.
ScacchiR, PintoA, RickardsO, et al. (2007) An analysis of peroxisome proliferator-activated receptor gamma (PPAR-gamma 2) Pro12Ala polymorphism distribution and prevalence of type 2 diabetes mellitus (T2DM) in world populations in relation to dietary habits. Nutr Metab Cardiovasc Dis, 17:632-41.
50.
SchneiderJ, KreuzerJ, HamannA, et al. (2002) The proline12alanine substitution in the peroxisome proliferator-activated receptor-γ2 gene is associated with lower lipoprotein lipase activity in vivo. Diabetes, 51:867-870.
51.
SchoonjansK, Peinado-OnsurbeJ, LefebvreAM, et al. (1996) PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J, 15:5336-5348.
52.
SemenkovichCF, WimsM, NoeL, et al. (1989) Insulin regulation of lipoprotein lipase activity in 3T3-L1 adipocytes is mediated at posttranscriptional and posttranslational levels. J Biol Chem, 264:9030-9038.
53.
SharmaAM, StaelsB (2007) Review: Peroxisome proliferator-activated receptor gamma and adipose tissue—understanding obesity-related changes in regulation of lipid and glucose metabolism. J Clin Endocrinol Metab, 92:386-395.
54.
StephensJW, HurelSJ, CooperJA, et al. (2004) A common functional variant in the interleukin-6 gene is associated with increased body mass index in subjects with type 2 diabetes mellitus. Mol Genet Metab, 82:180-186.
55.
StephensJW, HurelSJ, LoweGDO, et al. (2007) Association between plasma IL-6, the IL6-174G>C gene variant and the metabolic syndrome in type 2 diabetes mellitus. Mol Genet Metab, 90:422-428.
56.
TiretL, BlancH, RuidavetsJB, et al. (1998) Gene polymorphisms of the renin-angiotensin system in relation to hypertension and parental history of myocardial infarction and stroke: the PEGASE study. Projet d'Etude des Genes de l'Hypertension Arterielle Severe a moderee Essentielle. J Hypertens, 16:37-44.
57.
TiretL, RigatB, VisvikisS, et al. (1992) Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels. Am J Hum Genet, 51:197-205.
58.
XuE, LiW, ZhanL, et al. (2008) Polymorphisms of the lipoprotein lipase gene are associated with atherosclerotic cerebral infarction in the Chinese. Neuroscience, 155:403-408.
